Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Guggenheim Analyst Says

Arcutis Biotherapeutics (NASDAQ:ARQT) had its target price increased by equities research analysts at Guggenheim from $34.00 to $35.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s target price suggests a potential upside of 29.77% from the company’s current price.

ARQT has been the subject of a number of other research reports. HC Wainwright lifted their target price on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen downgraded Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. TD Cowen upped their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. Finally, Needham & Company LLC boosted their price target on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $26.97 on Friday. The stock has a fifty day moving average price of $27.24 and a 200 day moving average price of $23.86. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The stock has a market cap of $3.35 billion, a PE ratio of -192.63 and a beta of 1.70. Arcutis Biotherapeutics has a 1 year low of $11.86 and a 1 year high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 11.01% and a negative net margin of 4.29%.The company had revenue of $129.50 million for the quarter, compared to analyst estimates of $110.79 million. Sell-side analysts forecast that Arcutis Biotherapeutics will post -1.33 earnings per share for the current fiscal year.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 19,833 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $505,741.50. Following the completion of the sale, the insider directly owned 721,306 shares of the company’s stock, valued at approximately $18,393,303. The trade was a 2.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry Todd Edwards sold 2,052 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $52,326.00. Following the completion of the transaction, the insider owned 148,865 shares of the company’s stock, valued at $3,796,057.50. The trade was a 1.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 124,656 shares of company stock worth $3,312,365 in the last three months. 9.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARQT. Focus Partners Wealth raised its stake in Arcutis Biotherapeutics by 0.8% during the third quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after purchasing an additional 490 shares during the period. Arizona State Retirement System increased its holdings in shares of Arcutis Biotherapeutics by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock worth $597,000 after buying an additional 568 shares during the last quarter. Schroder Investment Management Group raised its position in shares of Arcutis Biotherapeutics by 1.1% in the 4th quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock worth $1,604,000 after buying an additional 594 shares during the period. AlphaQuest LLC boosted its holdings in Arcutis Biotherapeutics by 5.7% in the third quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock valued at $238,000 after acquiring an additional 682 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after acquiring an additional 698 shares during the last quarter.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Solid Q4 results and revenue beat — Arcutis reported a robust Q4 with revenue growth and a GAAP EPS beat, driven by Zoryve adoption; the quarter and raised guidance underpin the bullish view on commercial execution. Arcutis Biotherapeutics surges on earnings beat, raised guidance
• Positive Sentiment: Multiple analyst price-target increases — Needham, TD Cowen and Guggenheim raised targets (to the mid-$30s) and maintain buy ratings, signaling analyst confidence in growth and creating upside narrative for the stock. Benzinga coverage of analyst price-target changes
• Positive Sentiment: Bull case coverage highlights pipeline and label-expansion catalysts — Recent analyst and media pieces emphasize Zoryve market leadership, operating leverage and upcoming pediatric/label catalysts that could support longer-term upside. Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
• Neutral Sentiment: Investor presentation scheduled — Management will present at TD Cowen’s healthcare conference next week, giving investors an opportunity for updated guidance/visibility; this is a near-term catalyst but not an immediate earnings event. Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
• Neutral Sentiment: Broad coverage and transcripts available — Earnings call transcript and multiple recaps give investors transparency into execution and guidance; this helps short- and long-term assessment but is informational. Arcutis (ARQT) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Near-term EPS cuts by HC Wainwright — Despite maintaining a Buy and $34 target, HC Wainwright lowered Q2–Q4 2026 EPS estimates, which can temper short-term sentiment and provide a rationale for profit-taking after the post-earnings rally.
• Negative Sentiment: Mixed/unclear short-interest data — Recent short-interest reports appear inconsistent (zero/NaN entries), creating uncertainty about downside pressure from traders; unclear short-covering dynamics can add volatility.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.